Glucagon‐like peptide‐1 receptor agonist and respiratory complications after endoscopy: A Japanese nationwide cohort study
Main finding · Overall respiratory complicationsResult — go to the resultOdds ratio 0.79 95% CI 0.44–1.40Authors' conclusion
GLP-1RA was not associated with increased post-EGD respiratory complications, suggesting that routine discontinuation may be unnecessary for many stable, long-term users. However, our findings do not support a uniform conclusion of safety for all subgroups. The non-significant trends in new users and patients with severe diabetes warrant a cautious, individualised approach for these potentially vulnerable populations. Further research is needed to definitively clarify this risk.
Study context
- Population
- Patients with diabetes undergoing esophagogastroduodenoscopy (EGD), Japan Medical Data Center database; matched on age, sex, insulin use, HbA1c, chronic respiratory disease and BMImatched cohort
- Participants
- 3,568 vs 14,246
- Exposure
- GLP-1 RA users vs non-users
- GLP-1RAn = 3,568
- Non-usersn = 14,246reference
- Outcome
- Respiratory complications post-EGD
- Follow-up
- Within 14 days
Methodological detailsnationwide, 1:4 propensity score matching
- Nationwide
- 1:4 propensity score matching
Main finding
Overall respiratory complications · within 14 days post-EGD
Odds ratio
0.79
95% CI 0.44–1.40
P = 0.41
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | GLP-1RA | Non-users | OR | P value | |
|---|---|---|---|---|---|
| Severe respiratory complications · within 14 days post-EGD | 0.11% | 0.077% | 1.45 (CI 0.46–4.56) | P = 0.52 | |
| Respiratory complications, subgroup: new users | 1.43 (95% CI 0.51–3.98) | ||||
| Respiratory complications, subgroup: severe diabetes | 1.28 (95% CI 0.64–2.52) | ||||
| 0.20.5125Odds ratio (log scale) |
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →